Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|April 15, 2021
- Ophthalmology Times: April 15, 2021
- Volume 46
- Issue 7
Sunset eyes
Author(s)Jon Carter
Check out the latest cartoon!
Advertisement
Articles in this issue
over 5 years ago
Multicolor and autofluorescence imaging: What’s in a name?over 5 years ago
Optical dispensary conversionsover 5 years ago
Results from ophthalmology/rheumatology clinic treating uveitisover 5 years ago
Study confirms efficacy of uveitis treatmentover 5 years ago
Strategies to address challenging ocular infectionsover 5 years ago
Wet AMD: Current therapies and treatmentover 5 years ago
Standalone MIGS delivers durable IOP control in phakic eyesAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
3
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
4
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
5